Clinical Trials Logo
  1. Home
  2. Sepsis
  3. NCT05246969
  4. Details
NCT05246969 Clinical Trial

Detecting Sepsis in Patients With Severe Subarachnoideal Hemorrhage

Sepsis Clinical Trial

Official title:
Detecting Sepsis in Patients With Severe Subarachnoideal Hemorrhage

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05246969
Other study ID # Sepsis in SAH
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2017
Est. completion date February 1, 2022

Study information
Verified date March 2022
Source Goethe University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study aims to evaluate the suitability of the SOFA score implemented by the Sepsis 3 guideline to detect sepsis in patients suffering from subrarachnoid hemorrhage.

Recruitment information / eligibility
Status Completed
Enrollment 58
Est. completion date February 1, 2022
Est. primary completion date June 1, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Critically ill patients suffering from moderate to severe subarachnoid hemorrhage (WFNS >2). Exclusion Criteria: children under the age of 18 years Patients with minor subarachnoid hemorrhage < WFNS stage 2.

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Sepsis detection
The aim of the study was to observe whether the treating physicians were able to detect sepsis by strictly applying the recommended SOFA score.

Locations
Country Name City State
Germany University Hospital Frankfurt Frankfurt Niederrad Hessen

Sponsors (1)
Lead Sponsor Collaborator
Goethe University

Country where clinical trial is conducted

Germany, 

Outcome
Type Measure Description Time frame Safety issue
Primary Sepsis SOFA positive Sepsis correctly detected by SOFA score (Sepsis-related organ failure assessment score, 0-24 points) up to 2 months
Primary Sepsis SOFA negative Sepsis not detected by SOFA score (Sepsis-related organ failure assessment score, 0-24 points) up to 2 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A